The EANM guideline on radioiodine therapy of benign thyroid disease

Alfredo Campennì; Anca M Avram; Frederik A Verburg; Ioannis Iakovou; Heribert Hänscheid; Bart de Keizer; Petra Petranović Ovčariček; Luca Giovanella

doi:10.1007/s00259-023-06274-5

The EANM guideline on radioiodine therapy of benign thyroid disease

Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3324-3348. doi: 10.1007/s00259-023-06274-5. Epub 2023 Jul 3.

Authors

Alfredo Campennì¹, Anca M Avram², Frederik A Verburg³, Ioannis Iakovou^{4

5}, Heribert Hänscheid⁶, Bart de Keizer⁷, Petra Petranović Ovčariček^{8

9}, Luca Giovanella^{10

11}

Affiliations

¹ Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Unit of Nuclear Medicine, University of Messina, Messina, Italy.
² Departments of Radiology and Medicine, MetroHealth Hospital, Case Western Reserve University, Cleveland, OH, USA.
³ Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands. [email protected].
⁴ Academic Department of Nuclear Medicine, University Hospital AHEPA, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
⁵ Academic Department of Nuclear Medicine, General Hospital Papageorgiou, Aristotle University of Thessaloniki, Thessaloniki, Greece.
⁶ Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
⁷ Department of Radiology and Nuclear Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands.
⁸ Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia.
⁹ School of Medicine, University of Zagreb, Zagreb, Croatia.
¹⁰ Clinic for Nuclear Medicine, Ente Ospedaliero Cantonale, Imaging Institute of Southern Switzerland, Bellinzona, Switzerland.
¹¹ Clinic for Nuclear Medicine, University Hospital and University of Zurich, Zurich, Switzerland.

Abstract

This document provides the new EANM guideline on radioiodine therapy of benign thyroid disease. Its aim is to guide nuclear medicine physicians, endocrinologists, and practitioners in the selection of patients for radioiodine therapy. Its recommendations on patients' preparation, empiric and dosimetric therapeutic approaches, applied radioiodine activity, radiation protection requirements, and patients follow-up after administration of radioiodine therapy are extensively discussed.

Keywords: Dosimetry; Fixed activity; Graves’ disease; Non-toxic goiter; RAI therapy; Toxic nodular goiter.

MeSH terms

Graves Disease* / drug therapy
Humans
Iodine Radioisotopes / therapeutic use
Radiation Protection*
Radiometry
Thyroid Diseases* / drug therapy
Thyroid Diseases* / radiotherapy

Substances

Iodine Radioisotopes